NEW YORK – Daiichi Sankyo and AstraZeneca have begun a Phase II clinical trial of datopotamab deruxtecan in non-small cell lung cancer with actionable genomic alterations.
The global, single-arm trial, called TROPION-Lung05, is evaluating the treatment in NSCLC patients with a variety of activating alterations in genes, such as EGFR, ALK, ROS1, NTRK, BRAF, MET, or RET. Participants must have cancer that has progressed despite treatment with a tyrosine kinase inhibitor and platinum-based chemotherapy with or without other systemic therapies.